Live feed16:05:00·1748dPRReleasevia QuantisnowApellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022ByQuantisnow·Wall Street's wire, on your screen.APLS· Apellis Pharmaceuticals Inc.Health Care
